The New England Journal of Medicine JULY 25, 2013

Riociguat for the Treatment of Pulmonary Arterial Hypertension (PATENT-1)

Ardeschir J. Ghofrani, Hossein-Ardeschir Ghofrani, et al.

Bottom Line

The PATENT-1 trial demonstrated that oral riociguat significantly improved 6-minute walk distance and secondary hemodynamic parameters in patients with symptomatic pulmonary arterial hypertension.

Key Findings

1. Patients receiving individualized doses of riociguat (up to 2.5 mg three times daily) achieved a significant improvement in the primary endpoint of 6-minute walk distance (6MWD), with a least-squares mean increase of 36 meters compared to placebo at week 12 (95% CI, 20 to 52; P<0.001).

2. Secondary endpoints showed significant improvement, including a reduction in pulmonary vascular resistance (mean difference of -226 dyn·sec·cm-5 compared to placebo, P<0.001) and a decrease in NT-proBNP levels.

3. The treatment was generally well-tolerated, with a safety profile comparable to the placebo group, although headache, dyspepsia, and dizziness were common reported adverse events.

Study Design

Design

RCT

Double-Blind

Sample

443

Patients

Duration

12 wk

Median

Setting

Multicenter, international

Population Symptomatic pulmonary arterial hypertension (PAH) patients, including those treatment-naive and those on stable background therapy (endothelin-receptor antagonists or oral prostanoids).

Intervention Oral riociguat, dose-adjusted up to 2.5 mg three times daily.

Comparator Placebo

Outcome Change from baseline to week 12 in 6-minute walk distance (6MWD).

Study Limitations

• Approximately half of the study participants were already receiving background PAH-targeted therapies, making it difficult to isolate the incremental benefit of riociguat versus its use as monotherapy.

• The trial was of relatively short duration (12 weeks), limiting long-term assessment of efficacy and safety, which required subsequent analysis from the PATENT-2 extension study.

• The 6-minute walk distance is a surrogate endpoint that may not fully reflect clinical outcomes like mortality or heart failure hospitalization.

Clinical Significance

PATENT-1 established riociguat as the first-in-class soluble guanylate cyclase (sGC) stimulator approved for PAH, offering a distinct mechanism of action compared to conventional PDE5 inhibitors and prostacyclin pathway agents.

Historical Context

Prior to riociguat, therapeutic options for PAH were primarily limited to endothelin receptor antagonists, phosphodiesterase-5 (PDE5) inhibitors, and prostanoids, all of which targeted the NO-sGC-cGMP pathway indirectly; riociguat directly stimulates sGC, providing a unique pharmacological strategy.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Describe the specific mechanism of action of riociguat and explain how its interaction with the nitric oxide (NO) pathway distinguishes it from phosphodiesterase-5 (PDE5) inhibitors.

Key Response

Riociguat is a soluble guanylate cyclase (sGC) stimulator. Unlike PDE5 inhibitors, which require endogenous NO to prevent cGMP breakdown, riociguat has a dual mechanism: it sensitizes sGC to endogenous NO and directly stimulates sGC independently of NO. This is physiologically significant in PAH where NO bioavailability is often severely depleted.

Resident

In the management of a patient with Pulmonary Arterial Hypertension (PAH), what are the clinical implications of the 'individualized titration' strategy used in the PATENT-1 trial regarding blood pressure monitoring and drug-drug interactions?

Key Response

PATENT-1 utilized an 8-week titration phase (0.5 mg to 2.5 mg tid) based on systolic blood pressure and clinical symptoms. Residents must recognize that systemic hypotension is the dose-limiting toxicity. Crucially, riociguat is strictly contraindicated with PDE5 inhibitors or nitrates due to the risk of profound, synergistic hypotension.

Fellow

The PATENT-1 trial included both treatment-naive patients and those previously treated with endothelin receptor antagonists (ERAs) or prostanoids. Analyze how these results influenced the transition toward sequential combination therapy in modern PAH algorithms.

Key Response

PATENT-1 demonstrated that riociguat improved 6MWD and PVR even in patients already receiving ERAs or inhaled prostanoids (roughly 50% of the cohort). This provided early evidence for the 'add-on' strategy to target multiple pathogenic pathways (NO, endothelin, and prostacyclin) to achieve lower risk status, a cornerstone of current ESC/ERS and ATS/CHEST guidelines.

Attending

While PATENT-1 showed a significant 36-meter improvement in 6MWD, how should the attending physician interpret the discordance between functional capacity improvements and the lack of a statistically significant reduction in mortality within the 12-week study period?

Key Response

12 weeks is insufficient to capture mortality benefits in PAH trials. The attending must teach that while 6MWD is a regulatory-friendly endpoint, it is a surrogate. Practice-changing insights involve looking at the secondary 'time to clinical worsening' and hemodynamic improvements (PVR reduction) as markers of right ventricular unloading, which are more predictive of long-term survival than walk distance alone.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

Critique the use of an individualized dose-titration design in PATENT-1. How does this approach impact the power of the study to detect a dose-response relationship compared to a fixed-dose allocation strategy?

Key Response

Individual titration maximizes the treatment effect for the primary endpoint (6MWD) by ensuring each patient reaches their maximum tolerated dose, potentially increasing study power. However, it conflates the dose-response relationship with inter-individual pharmacokinetic variability, making it difficult to determine if a specific dose level is universally superior or if the benefit is purely driven by titration to physiological effect.

Journal Editor

As a reviewer, what concerns would you raise regarding the generalizability of PATENT-1 findings given the exclusion of patients with significant underlying lung disease or left heart disease, and the relatively short 12-week primary endpoint?

Key Response

Editors would flag the 'clean' patient population as a potential threat to external validity, as many real-world PAH patients have comorbidities (Group 2 or 3 features). Furthermore, the 12-week duration is a 'red flag' for assessing the durability of response and safety (e.g., hemoptysis, which emerged as a concern in later post-marketing surveillance).

Guideline Committee

Does the evidence from PATENT-1 justify recommending riociguat as a first-line monotherapy, and how does its recommendation level compare to PDE5 inhibitors in the current ESC/ERS guidelines for patients with idiopathic PAH?

Key Response

PATENT-1 provided Level A, Class I evidence for riociguat in PAH. While current guidelines (e.g., 2022 ESC/ERS) place it on par with PDE5 inhibitors for treatment-naive patients at intermediate-low risk, riociguat holds a unique Class I recommendation for CTEPH (CHEST-1 trial), which often influences its selection in centers where the differential between PAH and CTEPH is narrow.

Clinical Landscape

Noteworthy Related Trials

2002

BREATHE-1 Trial

n = 213 · NEJM

Tested

Bosentan

Population

Patients with WHO functional class III or IV pulmonary arterial hypertension

Comparator

Placebo

Endpoint

Change from baseline in 6-minute walk distance

Key result: Bosentan treatment significantly improved exercise capacity and delayed clinical worsening in patients with PAH.

2013

SERAPHIN Trial

n = 742 · NEJM

Tested

Macitentan

Population

Symptomatic pulmonary arterial hypertension

Comparator

Placebo

Endpoint

Time from initiation of treatment to the first occurrence of a morbidity or mortality event

Key result: Macitentan therapy significantly reduced the risk of morbidity and mortality among patients with pulmonary arterial hypertension.

2015

AMBITION Trial

n = 500 · NEJM

Tested

Initial combination therapy with ambrisentan and tadalafil

Population

Treatment-naive pulmonary arterial hypertension

Comparator

Monotherapy with ambrisentan or tadalafil

Endpoint

Time to the first clinical failure event

Key result: Initial combination therapy significantly reduced the risk of clinical failure compared with monotherapy in patients with PAH.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis